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ABSTRACT
Background: According to several guidelines, the assessment of post-
menopausal fracture risk should be based on clinical risk factors (CRFs)
and bone density. Because measurement of bone density by dual x-ray
absorptiometry (DXA) is quite expensive, there has been increasing inter-
est to estimate fracture risk by CRFs.
Objective: The aim of this study was to determine the cost-effectiveness of
osteoporosis screening of CRFs with and without DXA compared with no
screening in postmenopausal women in Germany.
Methods: A cost-utility analysis and a budget-impact analysis were per-
formed from the perspective of the statutory health insurance. A Markov
model simulated costs and beneﬁts discounted at 3% over lifetime.
Results: Cost-effectiveness of CRFs compared with no screening is €4607,
€21,181, and €10,171 per quality-adjusted life-year (QALY) for 60-, 70-,
and 80-year-old women, respectively. Cost-effectiveness of DXA plus
CRFs compared with CRFs alone is €20,235 for 60-year-old women. In
women above the age of 70, DXA plus CRFs dominates CRFs alone. DXA
plus CRFs results in annual costs of €175 million, or 0.4% of the statutory
health insurance’s annual budget.
Conclusion: Funders should be careful in adopting a strategy based on
CRFs alone instead of DXA plus CRFs. Only if DXA is not available,
assessing CRFs only is an acceptable option in predicting a woman’s risk
of fracture.
Keywords: cost-utility analysis, modeling, osteoporosis, secondary preven-
tion, women’s health.
Introduction
Osteoporosis, amultifactorial disorder resulting in increased bone
fragility, occurs in women after menopause and is one of the most
important disorders affecting the elderly [1]. Population aging is
expected to increase the number of osteoporosis-related fractures
such as hip fractures and, hence, the economic burden for society.
Bone mineral density (BMD) is considered an important pre-
dictive factor for osteoporotic fractures and is measured by den-
sitometry. Densitometry results are usually reported as a t-score,
which is the number of standard deviations between the value of
an individual and the mean value of a group of young adults of
the same sex [2]. According to the criteria of the World Health
Organization (WHO) osteoporosis is deﬁned by a t-score of
-2.5 [3]. If bone density is measured by dual x-ray absorpti-
ometry (DXA), the risk of hip fracture (other fractures) increases
by a factor between 3.7 (1.2) at age 50 and 1.7 (1.6) at age 90 for
each standard deviation decrease in BMD at the femoral neck [4].
This increase in fracture risk for each standard deviation change
is called the gradient of risk (GR/SD) [4].
DXA is expensive, not available everywhere, and to a certain
degree unreliable because BMD can vary by up to 20% to 50%
around an individual’s true BMD [5]. Furthermore, different
scanners for bone density used in the same patients vary con-
siderably in the proportion of those who receive a diagnosis
of osteoporosis [6]. While, in Germany, the prevalence of
osteoporosis in women varies between 7% (age: 55) and 19%
(age: 80) [7], the majority of fractures occur in women who do
not have osteoporosis [7]. Thus, the use of DXA in primary or
secondary prevention is disputed [8].
Recently, several risk factors for fracture have received atten-
tion [9]. These include prior fragility fractures, a family history of
hip fracture, low body mass index (BMI), smoking, alcohol
intake, and the use of oral corticosteroids. Combinations of these
risk factors were used to develop decision rules for BMD referrals
[10]. Although a case ﬁnding based on DXA alone (compared
with fractures that will occur in the following 10 years) has a
speciﬁcity (proportion of true-negatives) of approximately 90%,
its sensitivity (proportion of true-positives) is only 34% [11].
Different strategies based on CRFs alone, in turn, have shown to
exceed a sensitivity of 80% although their speciﬁcity is only
about 50% (compared with the reference standard low BMD
measured by DXA) [12]. Thus, predicting fracture risk based on
CRFs in addition to BMD increases the GR for the prediction of
hip and other fractures [4]. As a result, the sensitivity and the
positive predictive values (proportion of women with positive
test results who will have a fracture in the following 10 years)
increase [13,14].
To guide treatment based on a combined use of CRFs and
BMD, several organizations recently have recommended using
CRFs and BMD to assess an individual’s absolute 10-year risk of
fracture [9,15] or annual incidence of fracture [16]. According to
the German osteology umbrella organization, Dachverband Oste-
ologie (DVO) guideline, DXA should be provided for women
when there is a 10-year risk of combined vertebral (clinical and
morphometrical) and hip fractures of 20%. Drug treatment
should be provided for women with a combined risk of30% for
vertebral and hip fractures [7]. The t-score required to reach this
risk threshold varies by age. A 55-year-old woman, for example,
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receives treatment for a t-score of -4, whereas a 67-year-old
woman receives it based on a t-score of -3. Additional risk factors
further increase the t-score required to reach the threshold [7].
While this and other recently developed screen-and-treat
strategies agree that CRFs should be given more attention, treat-
ment recommendations still tend to center on DXA [7,15,16].
Although the combined use of DXA and CRFs improves the
GR/SD [4], for women aged >65 years, its sensitivity is only 60%
even if a risk threshold of 30% is chosen [13]. This is an increase
of 80% compared with DXA alone in women aged 70 to 79
years, but the price to pay for this improvement is a decrease in
speciﬁcity by 16% [11,13]. The usage of CRFs alone, however,
may be of diagnostic value for predicting fracture risk because
age-speciﬁc GRs are similar to those of BMD alone [4]. Thus, a
strategy where fracture risk is calculated by CRFs alone may
improve the cost-effectiveness compared with an expensive
DXA-centered strategy. The National Institute for Health and
Clinical Excellence, for example, recommends bisphosphonates
in postmenopausal women aged 75 years and older even without
the need for DXA if the clinician considers DXA to be clinically
inappropriate or unfeasible [16].
In the vast majority of cost-effectiveness analyses on post-
menopausal osteoporosis treatment, women at increased risk
were selected by low BMD [17]. Nevertheless, the use of CRFs as
a prescreening tool for DXA (i.e., DXA only for those women
with elevated CRFs) has been shown to be cost-effective when
compared with mass screening with DXA alone [18]. In addition,
there are two modeling studies that analyzed the cost-
effectiveness of treatment in postmenopausal women, based on
long-term fracture risk rather than on BMD alone [19,20]. In
contrast to our analysis, these studies did not consider treatment
costs of false positives, selected women at increased risk based on
additional risk factors (e.g., BMI or the use of oral glucocorti-
coids), used a 10-year modeling horizon, and assumed that
beyond 10 years, women would have a mortality rate equal to
that of an age- and sex-matched population [19,20,21].
The present study investigated the cost-effectiveness of the
following strategies: 1) screening based on CRFs alone (without
information about BMD) and treatment with alendronate in case
of risk of 30% (age groups 60–70 and 70–80), or treatment
with alendronate for all women (age group: 80–90); 2) screening
with DXA plus CRFs (plus alendronate); and 3) no screening
(Fig. 1). While different medical treatment options are recom-
mended, we chose alendronate, an antiresorptive biphosphonate,
as the sole drug because, in our previous cost-utility analysis, it
has shown to be most cost-effective [22].
Methods
The analysis was performed from the perspective of the German
statutory health insurance (SHI). For the base case we considered
a cohort of 10,000 women aged 60, 70, and 80 years. Because
patients with osteoporosis face fracture risk that is continuous
over time, we developed a Markov model in Microsoft Excel
Age
group*
Absolute risk of 20% 
(for subsequent 
fractures)  
Absolute risk of 30% 
(for subsequent 
fractures)†
60-70 
(9.5%) 
Treatment for women 
with a prior vertebral 
fracture 
CRFs
70-80 
(23.2%) 
Treatment for women 
with one or more 
additional risk factor 
80-90 
(53.2%) 
Treatment for  
all women  
60-70 
Treatment for women
with a T-score of < -3.5
(65: -3.0 or less)
DXA + CRFs 
> 70 
DXA for  
all women  
Treatment for women 
with a T-score of < -2.5
(>75: -2.0 or less) 
No screening 
DXA for women
with one or more
additional risk factor
Figure 1 Overview of screen-and-treat strategies
(clinical risk factors (CRFs) alone, dual x-ray
absorptiometry (DXA) plus CRFs, no screening).
*Numbers in parentheses indicates the 10-year
risk of vertebral and hip fractures in women of this
age group. †The true bone mineral density (BMD)
of women in the CRFs group is unknown because
women in this group can have normal, osteopenic,
or osteoporotic BMD.
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2003 (Microsoft Corporation, Redmond, WA). The health
beneﬁt was estimated in terms of quality-adjusted life-year
(QALYs), and incremental cost-effectiveness ratios (ICERs) were
calculated. Preference weights are expressed by values between 1
for perfect health and 0 for the death [23]. A budget impact
analysis (BIA) was performed by multiplying incremental costs
per woman by the number of women who are insured by the SHI
[24]. The BIA included future costs for unrelated health condi-
tions during added years of life. The annual expected resource
use for the SHI was estimated based on public databases [24,25].
Lost productivity was not included in the BIA because it is not
relevant to the expenditure side of the SHI. As recommended for
chronic diseases, a lifetime horizon was chosen [26].
Overview and Model Design
The Markov model uses age-speciﬁc fracture rates. The cycle
length is 1 year because transition probabilities obtained from
the literature refer to periods of at least 1 year. The model starts
with a cohort of high-risk women who are identiﬁed on the basis
of CRFs with and without DXA and who have a combined
10-year risk of 30% for vertebral and hip fractures. It stops at
the age of 100 because, for Germany, there are no survival data
beyond the age of 100 [27]. There are eight health states (Fig. 2):
no fracture (30% probability of fracture in the 10 years from
the start of the model), three-fracture states (hip, vertebral, and
forearm), the corresponding postfracture states, and death. All
women start in a state with a long-term risk of 30%. For each
cycle, there is a deﬁned probability of staying in the no-fracture
state, experiencing a fracture, or dying. A woman who is in a
fracture state can have another fracture at the same or another
site. Women, who have a fracture change to the postfracture
state, stay in the same fracture state if they have a refracture,
change to another fracture state, or die. We conducted a half-
cycle correction. Costs and beneﬁts were discounted at an annual
rate of 3% [28]. All costs are presented in euros and year 2006
values and were adjusted for inﬂation based on the German
Consumer Price Index [29].
The structure of this Markov cohort model is similar to that
of an established reference model [30]. As recommended there, a
lifelong time horizon with a cycle length of 1 year was used,
effectiveness was assumed to decrease linearly for a given “offset
time,” and fracture states for hip, vertebral, and forearm were
modeled [30]. In contrast to the reference model, in our model, a
woman may suffer a vertebral or forearm fracture after a hip
fracture. Excess mortality after hip or vertebral fracture was
modeled as well as the conservative assumption that costs of
vertebral and wrist fractures only incur during the ﬁrst year after
the fracture. Although a state for other osteoporotic fractures
was not modeled, for all fracture sites included in the analysis,
postfracture states were added to reﬂect a persistent decrease in
health-related quality of life (QoL) (hip, vertebral fractures) and
the sustained risk increase for subsequent fractures.
Data
Efﬁcacy/Effectiveness. Data on effectiveness of alendronate were
taken from a meta-analysis that was based on large randomized
controlled trials [31]. While effectiveness data on high-risk
women selected by DXA were restricted to patients with
osteoporosis or severe osteoporosis, effectiveness data on high-
risk women selected by CRFs were also based on osteopenic
women [31], resulting in lower effectiveness in women selected
by CRFs.
Alendronate was offered for 4 years, which is in the range of
recommended treatment duration in Germany (3–5 years) [7].
Effectiveness was assumed to decrease in linearly over a period of
4 years after the last intake [32]. Basing on the effectiveness data
used for our analysis, we assumed that alendronate has no rele-
vant side effects [31].
Medication compliance (or adherence) for individuals with
chronic diseases such as osteoporosis is poor. Compliance is
deﬁned as the “extent to which a patient acts in accordance
with the prescribed interval and dose of a dosing regimen” [33].
To adjust drug effectiveness and costs for the rate of noncom-
pliance in the real world, we multiplied effectiveness (at full
compliance) and costs of alendronate and checkups by the
“medication possession ratio” (the number of doses dispensed
in relation to the dispensing period [33]) for daily intake of oral
bisphosphonates (more than 12 months) using German pre-
scription data [34]. Persistence, which is deﬁned as “the dura-
tion of time from initiation to discontinuation of therapy” [33],
was not modeled.
Hip
fracture
Vertebral
fracture
Forearm 
fracture
Post fracture 
state (vertebral)
Post fracture 
state (forearm)
≥ 30% risk of 
fracture
Death
Post fracture 
state (hip)
Figure 2 Health states.
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Absolute long-term risk and incidence. The number of women at
risk was taken from the DVO guideline, which modeled an
absolute 10-year fracture risk for the German population, based
on published data on population age, prior vertebral fractures,
and bone density [35,36].
In women below the age of 80, incidence rates of the general
population [37–39] were increased to be at the level of the
average fracture risk in women above the treatment threshold.
The average risk in a group of women selected by CRFs depends
on the GR and the ratio of the chosen risk threshold to the
population risk. If treatment is provided on the basis of CRFs
alone, the GR varies from 1.4 to 2.1, depending on age and
fracture site [4]. An absolute risk of 30% in the age group of 70
to 80, e.g., means that this threshold equals 1.3 times the popu-
lation risk, although the average risk, which is higher than the
threshold, equals 1.9 times the population risk for hip fracture
and 1.7 times for vertebral or forearm fractures, respectively
[14] (details of formulae used for calculations of incidence
can be found at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH12i8_Mueller.asp). In women above the
age of 80, incidence rates of the general population were used
because all women receive treatment.
For women with a prior fracture, we assumed that the risk
increases for all subsequent fractures. The risk of a woman who
suffered fractures in two or more different sites was assumed to
be determined only by the last fracture. The magnitude of the risk
increase depends on the location of the prior fracture [40].
Mortality and health-related QoL. Mortality data were obtained
from a public database of the Federal Statistical Ofﬁce (Wies-
baden, Germany) [41] and were adjusted for women at increased
risk [42–44]. Long-term mortality and life expectancy associated
with hip fractures were modeled in a previous article [45]. In this
model, inpatient mortality was based on a high-quality study
analyzing the volume–outcome relationship of hip fracture
surgery in German hospitals [46]. Mortality from revision sur-
geries was also considered in this model. QoL data were based on
the EuroQol, a preference-based questionnaire [47].
For the state “Long-term risk 30%,” we used QoL data of
the general population, that is, utility values of <1 for all ages,
estimated by a time trade-off questionnaire [48]. The reason is
that individuals with osteoporosis may suffer from additional
diseases causing disutility. QoL of women aged 60 to 70 years
was further reduced because, in this group, a long-term risk of
30% can only be reached if a woman had a prior vertebral
fracture [7]. QoL for forearm and clinical vertebral fractures was
also based on surveys that used the EuroQol [49]. Because a
value of 1 was assigned to the no-fracture state, data were
multiplied by health-related QoL (HR-QoL) data from the
general population [48]. For the postfracture states, we assumed
an improvement of QoL, though not to the prior level. These
values were not changed except when additional fractures
occurred or patients died. In women with a forearm fracture and
a prior vertebral fracture, we did not use values of forearm
fractures because these were higher than values for the status
post vertebral fracture. For women with a forearm or vertebral
fracture and a prior hip fracture, the lower preference weight of
the prior hip fracture was maintained.
Validity of the diagnosis. According to the DVO the combined
10-year risk of vertebral and hip fracture in the age group 60
to 70 is 10%. The threshold of 30% can only be reached if a
woman has had a vertebral fracture because other risk factors
do not increase the risk sufﬁciently [7]. A pretest x-ray is rec-
ommended in Germany for women with severe low-back pain
or moderate low-back pain for >4 weeks [50]. In Germany, the
1-year prevalence of back pain in women aged 60 to 70 years
is estimated to be 23% [51], and the proportion of these
women undergoing an x-ray is 35% [52]. Hence, only 8% of
all women in the model undergo a routine x-ray, provided that
all women with lasting back pain attend a physician. Never-
theless, this group includes only 35% of all vertebral fractures
because 65% are not recognized clinically [53]. Furthermore, in
women with clinically apparent fractures who undergo the
pretest, a high prevalence of unspeciﬁc back pain, morphologi-
cal changes, and misinterpreted x-rays confounds the validity of
the diagnosis [54]. As a result, 2.4% of all women screened
receive treatment with alendronate (90% of these women are
true-positive).
Because the 10-year risk of vertebral and hip fracture for
70- to 80-year-old women is already 23%, the German DVO
considers this risk to be 30% if a woman has a prior fracture,
has a parental history of a femur fracture, is a smoker, is immo-
bile, or has a tendency to fall [7]. This decision rule is consis-
tent with the case-ﬁnding strategy of the National Osteoporosis
Foundation, which is carried out to identify individuals with
osteoporosis compared with low BMD as a reference standard
[55,56]. Based on a t-score of -2.5, which in this age group
corresponds to the threshold of 30%, 85% of all women
undergo treatment because they are suspected as being at risk
as a result of one or more CRFs (26% of these women are
true-positive) [10].
All women aged >80 years receive drug treatment because the
therapeutic threshold of 30% is assumed to be reached by age
alone (Table 1).
The validity of DXA plus CRFs is extensively described in our
prior analysis [22]. Brieﬂy, for women aged 60 to 70 years, 24%
of all women screened receive treatment (23% of these women
are true-positive). In women the age of more than 70 and 80, the
proportion of women who undergo treatment is 33% (42% of
these are true-positive) and 44% (73%), respectively.
Costs
Our analysis considers the costs of screening as well as treatment
costs of false- and true-positives. General health-care costs in
added years of life were also taken into consideration. As a cost
of screening, we applied the costs of routine checkups, which
include a face-to-face interview, an evaluation of the medical
history, and a physical examination. Therefore, we assumed that
risk factors such as a prior fracture, a parental history of a femur
fracture, smoking, immobility, and tendency to fall are assessed
during routine visits and do not require speciﬁc equipment. The
costs of initial x-rays were not included because patients with
severe or persistent back pain in Germany routinely undergo an
x-ray [50].
Although costs of treating vertebral and forearm fractures
were calculated for the year of the fracture, they were not applied
to subsequent years [30], which is a conservative assumption.
Costs of treating hip fractures were taken from a recent German
analysis modeling long-term cost and effects of hip fracture sur-
geries, which includes costs of initial hospitalization for hip
implants, readmissions, transportation services, outpatient treat-
ment, rehabilitation, long-term care, and costs in added years of
life [45]. All long-term costs of hip fractures were considered,
including those of refractures. For double counting of refracture
costs to be avoided, a hip fracture can only occur once in the
Markov model. If a woman with a prior hip fracture suffered a
forearm or a vertebral fracture, the costs of this additional frac-
ture would be added to the costs of the hip fracture. Costs were
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stratiﬁed by age group. All input data used for the model
are described in Tables 2 and 3. Copayments by patients were
subtracted.
Sensitivity Analysis
We carried out a one-way sensitivity analysis for all model vari-
ables. In addition, a threshold analysis was performed to deter-
mine the level of risk at different cost-effectiveness thresholds.
The combined risk for vertebral and hip fractures was calculated
based on cost-effectiveness thresholds between €5000 and
€35,000. When varying the risk of vertebral and hip fractures
simultaneously, an equal relative risk increase or decrease was
assumed; that is, the relative risks of hip and vertebral fractures
were varied by the same factor.
To assess how a simultaneous change of several variables
affected the cost-effectiveness ratio, we performed a Monte Carlo
simulation of model variables listed in Tables 2 and 3 (except for
the discount rate as well as costs of checkups, alendronate, and
hospitalizations caused by vertebral and forearm fractures).
For variables on a scale between 0 and 1, we assumed a beta
distribution (0  q  1, a > 0, b > 0). For cost data, we assumed
a gamma distribution (a > 0 and b > 0), with the mean a/b and
the variance a/b2 [65]. We conducted 1000 iterations. Given that
the interpretation of negative cost-effectiveness ratios is ambigu-
ous, we transformed cost-effectiveness ratios into net monetary
beneﬁts (NMBs) using the following equation [66]:
NMB E C= ∗ −λ Δ Δ , (1)
where l = maximal willingness to pay, DE = incremental beneﬁt
(QALYs), and DC = incremental costs.
The decision rule we used was to adopt the screen-and-treat
strategies in question if NMB was greater than 0.
Results
Base-Case Analysis
The ICERs of a screen-and-treat strategy based on CRFs alone
versus no screening are below €22,000 in all age groups
(Table 4). Compared with women aged 70 to 80 years, the
increased absolute fracture risk in women aged >80 years makes
immediate treatment of all women more cost-effective. Using
DXA plus CRFs compared with CRFs alone (i.e., immediate
treatment in women aged 80–90 years), there is an increase in
QALYs in all age groups (Fig. 3). In women above the age of 70
years, a strategy based on DXA plus CRFs dominates a strategy
based on CRFs alone; that is, it is more effective but less expen-
sive. Although, in women aged 60 to 70 years, CRFs alone are
considerably more cost-effective than DXA plus CRF, less than
one quarter of women at increased risk are detected. In contrast,
DXA plus CRFs detects 58% of women at increased risk.
If a screen-and-treat strategy based on CRFs alone was imple-
mented in Germany, costs would total €560 million, or 0.4% of
the SHI’s total annual budget [67] (Table 5). The major cost
driver is treatment with alendronate for 5.4 million women
across all age groups including both high- and low-risk women.
Nevertheless, 60% of these women are not at risk (false-
positives). When providing DXA plus CRFs in women above the
age of 70 years, costs of DXA are offset by lower costs of
treatment for false-positives. Only in women aged 60 to 70 years
is DXA plus CRFs more expensive than CRFs alone. Thus, over
all age groups, a screening strategy based on DXA plus CRFs
decreases annual costs by €385 compared with a strategy with
CRFs alone (Table 5).
Sensitivity Analysis
One-way analysis. For the comparison of CRFs alone versus no
screening and of DXA plus CRFs versus no screening, efﬁcacy of
alendronate and the discount rate have the largest impact on the
cost-effectiveness ratio. Assuming a lower efﬁcacy of alendronate
or a higher discount rate increases the ratio of both comparisons
by 40% to 60%. In contrast, assuming a higher efﬁcacy or a
lower discount rate improves the cost-effectiveness ratio of both
comparisons by approximately 20%. Decreasing QoL for frac-
ture states or increasing the incidence, the risk increase in sub-
sequent fractures, or compliance improves the ICER by
approximately 25% and thus makes the use of CRFs or DXA
plus CRFs more favorable. Lower rates of these variable or
higher QoL increases the ICER to the same degree and makes
CRFs or DXA plus CRFs less favorable. Results are robust to the
variation of other variables.
When comparing DXA plus CRFs with no screening, a lower
GR increases the ratio between 30% and 90%. In contrast,
assuming a higher GR improves the cost-effectiveness ratio by
approximately 30% to 40%.
When comparing DXA plus CRFs with CRFs alone, base-
case results are robust to changes in most variables. Nevertheless,
when a lower GR is assumed, the increase in QALYs by adding
DXA is attenuated or even negative (age group: 70–80 years)
Table 1 Diagnostic performance of screening for osteoporosis based on clinical risk factors*
Age group (10-year risk of fracture in the general population)
60–70 (9.5%) 70–80 (23.2%) 80–90 (53.2%)
x-Ray vertebral fracture one risk factor
Test
+
Test
-
Test
+
Test
-
Fracture in 220 113 333 Fracture in 2,232 88 2,320 Treatment is recommended
for all women.T0–T10† T0–T10
No fracture in 24 448 472 No fracture in 6,313 1,367 7,680
T0–T10 T0–T10
244 561 805 8,545 1,455 10,000
Sensitivity = 0.660 PPV = 0.902 Sensitivity = 0.962 PPV = 0.261
Speciﬁcity = 0.950 NPV = 0.799 Speciﬁcity = 0.178 NPV = 0.940
(t-score = 2.5 or less)
*Figures presented are numbers of patients.The calculations of women at increased risk for the different age groups are based on an absolute 10-year fracture risk and a cohort of 10,000 women.
†Period of 10 years.
NPV, negative predictive value; PPV, positive predictive value.
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because the average risk decreases more in women identiﬁed by
DXA plus CRFs than in women identiﬁed by CRFs alone.
Assuming a higher GR improves the ICER of DXA plus CRFs by
25% to 50% compared with CRFs alone. Using less conservative
assumptions such as a higher risk increase by prior fractures
improves the cost-effectiveness ratio of DXA plus CRFs com-
pared with CRFs alone. Further details on this can be found
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12i8_Mueller.asp.
Threshold analysis. Using a threshold cost-effectiveness ratio of
€30,000, CRFs become cost-effective in women aged >60 years
with a combined average fracture risk of 10.3% (hip: 1.3%). For
a ratio of €10,000, this risk increases to 27.2% (3.7) (Fig. 3a).
Assuming all women identiﬁed for being at increased risk would
have a combined average fracture risk of exactly 30% (hip, age
60 years: 3.8%; age 70 years: 6.2%; age 80 years: 9.9%), the
ICERs are €9575 (age 60 years), €47,351 (age 70 years), and
€18,496 (age 80 years), respectively.
Using a threshold cost-effectiveness ratio of €30,000, DXA
plus CRFs compared with no screening becomes cost-effective
in women aged >60 years with a combined average fracture
risk of 25.3% (hip: 2.6%), in women aged >70 years with an
average fracture risk of 30.6% (6.3), and in those aged >80
years with a risk of 11.5% (5.0). Using a threshold ratio of
€10,000, the risks increases to 80.1% (14.4), 69.2% (15.5),
and 29.4% (13.6), respectively (Fig. 3). Assuming all women
identiﬁed for being at increased risk would have a combined
average fracture risk of exactly 30% (hip, age 60 years: 3.3%,
age 70 years: 5.8%, age 80 years: 12.8%), the ICERs are
Table 2 Cost data
Parameter*
Price per
unit (€)
Annual
frequency
Mean annual cost†
per patient (€) Reference
1. Diagnosis Routine visit (initial) 25.56 1 25.56 [57]
Check-ups (physician) 3 (year 1, 2) 76.68
1.5 (year 3, 4) 38.34
2. Medication Alendronate, 5–10 mg daily 1.20 365 438.00 [58]
3. Vertebral fractures
Outpatient treatment Consultation for osteoporosis with
pathological fracture (M80)
14.4 286.16 [25]
Physical therapy Physiotherapy (WS2) 14.50 18 234.90 [59,60]
Heat (WS2) 7.21 18 116.82
Ergotherapy (SB1) 23.80 20 428.40
Total of outpatient and physical
therapy
1,066.28
[853–1,279]
Inpatient treatment including
rehabilitation
3,222.00 [61,62]
4. Forearm fractures
Outpatient treatment Consultation for forearm fracture
(S52, 69% of all forearm fractures)
16 363.42 [25]
Consultation for wrist fracture
(S62, 31% of all forearm fractures)
14.4 295.15
Physical therapy S52 and S62 weighted 15.5 342.26
Physiotherapy (EX2/3) 14.50 24 313.00 [59,60]
Cryotherapy (EX2/3) 6.63 24 143.28
Lymphatic drainage (LY1) 13.04 12 140.88
Total of outpatient and physical
therapy
939.42
[752–1,127]
Inpatient treatment including
rehabilitation
3,174.00 [61,62]
5. Hip fractures‡§ (total costs) 50 years: 69,231 [45]
[67,289–71,443]
55 years: 62,591
[61,435–64,019]
60 years: 54,264
[52,674–55,887]
65 years: 47,837
[46,703–49,167]
70 years: 42,432
[41,287–43,664]
75 years: 39,586
[38,551–40,735]
80 years: 32,957
[32,087–33,878]
85 years: 29,417
[28,435–30,273]
90 years +: 26,187
[25,331–26,973]
6. Costs in added life years 60–65 years: 3,150 [63]
65–85 years: 6,150
>85 years: 12,405
*Diagnosis and treatment codes are shown in parentheses (for physical therapy, we used the German Heilmittelkatalog, for vertebral and forearm fractures ICD-10 numbers are cited).
†95% conﬁdence intervals are shown in parentheses. For outpatient treatment and physical therapy, we varied mean values by 20%. All costs are given in 2006 Euros and were adjusted for
inﬂation based on the German Consumer Price Index [29].
‡Lifetime costs discounted at 3% (this discounting applies only to hip fractures).
§These costs included costs of inpatient care in hospitals, hip replacements, revisions, readmissions, transportation services, outpatient treatment, rehabilitation, and long-term care.
For hip fractures, costs in added years of life are included in the total costs of hip fractures.
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€49,308 (age 60 years), €30,735 (age 70 years), and €9750 (age
80 years), respectively.
Monte Carlo simulation. Uncertainty in cost-effectiveness as
estimated by the Monte Carlo simulation is presented in the
cost-effectiveness acceptability curves in Figure 4. The probabil-
ity of CRFs alone or DXA plus CRFs being cost-effective depends
on the willingness to pay (WTP) for an additional QALY. In
women aged 60 to 70 years, both CRFs alone and DXA plus
CRFs are more likely to yield a higher net beneﬁt when societal
WTP for an additional QALY exceeds €10,000. Below this value,
no screening is more likely to be cost-effective in this age group.
At WTPs between €5000 and €35,000, CRFs are more cost-
effective than DXA plus CRFs. In women above 70 years, the
probability of cost-effectiveness of CRFs at each WTP is 0%. In
women aged >80 years, DXA plus CRFs is cost saving, with a
probability of 7% compared with CRFs alone or no screening.
Over all age groups, the higher the WTP, the more DXA plus
CRFs becomes the preferred strategy.
Discussion
This analysis presents data on the cost-effectiveness of two screen-
and-treat strategies in which the treatment threshold is deﬁned by
10-year risk of fracture, based on CRFs alone or DXA plus CRFs.
Comparedwith screeningwithDXAplusCRF, a strategy based on
CRFs alone is more expensive and less effective in women above
the age of 70 years. Note again that using CRFs implies treatment
of all women above the age of 80 years. Compared with no
screening, the cost-effectiveness of CRFs alone at an intervention
threshold of30% is fairly moderate in all age groups and similar
to those of other generally accepted medical interventions such as
hypertension treatment with thiazide diuretics in patients with
systolic blood pressure of 140 mm Hg [68].
Conclusions
Treatment should be based on bone density as long as DXA is
available for screening women above the age of 70 years. There-
Table 3 Input variables for the model (95% conﬁdence intervals or estimates thereof are shown in brackets)
Parameter Range (95% CI or estimates thereof) References
Incidence (%)* Vertebral fracture 60 years 0.95 (0.62–1.39), 65 years 1.23 (0.82–1.77), 70 years 1.79
(1.20–2.57), 75 years 2.93 (1.80–4.36)
[38]
Hip fracture 60 years 0.09, 65 years 0.16, 70 years 0.34, 75 years 0.70, 80 years
1.38, 85 years 2.94, 90 years 3.82, 95 years 3.06
[37]
Forearm fracture 60 years 0.49 (0.40–0.60), 65 years 0.58 (0.50–0.70), 70 years 0.73
(0.61–0.84), 75 years 0.71 (0.60–0.82), 80 years 0.77 (0.62–0.91),
85 years 1.04 (0.86–1.12), 90 years 0.94 (0.83–1.02)
[39]
10-year risk of fracture (%) 60 years 9.5 (7.6–11.4), 70 years 23.2 (18.6–27.8), 80 years 53.2
(42.6–63.8)
[7]
Relative mortality risk Osteoporosis 1.19 (1.04–1.36) [42]
Vertebral fracture 1.66 (1.51–1.80) for clinical fractures [43]
1.16 (1.03–1.30) for morphometrical fractures [44]
Relative risk of secondary fractures 60–90 years Initial fracture hip 2.79 (2.06–3.77) [40]
Initial fracture forearm 1.69 (1.35–2.12)
Initial fracture vertebral 2.52 (1.99–3.19)
Health-related quality of life No fracture (general
population data)
60 years 0.83 (0.78–0.88), 65 years 0.81 (0.75–0.86), 70 years 0.75
(0.69–0.80), 75 years 0.73 (0.67–0.79), 80 years 0.70 (0.61–0.78),
85 years 0.68 (0.59–0.76)
[48]
Fracture states Clinical vertebral, ﬁrst years 0.63 (0.50–0.75), [49]
Subsequent years 0.91 (0.83–0.98)
Morphometrical vertebral, ﬁrst years 0.82 (0.72–0.92),
Subsequent years 0.91 (0.84–0.99)
Forearm ﬁrst years 0.98 (0.96–1.00),
Subsequent years 1.00 (0.99–1.00)
Quality-adjusted life expectancy† Hip fracture 60 years 10.98 (8.97–12.34), 65 years 8.17 (6.4–10.17), 70 years 6.13
(4.79–7.69), 75 years 4.67 (3.65–5.97), 80 years 3.39 (2.41–4.58),
85 years 2.55 (1.78–3.54), 90 years 1.64 (1.32–2.21)
[45]
Relative fracture risk (alendronate) CRFs Forearm: 0.64 (0.30–1.35), hip: 0.62 (0.40–0.98), vertebral 0.56
(0.46–0.68)
[31]
DXA plus CRFs Forearm: 0.48 (0.31–0.75), hip: 0.46 (0.23–0.91), vertebral: 0.53
(0.42–0.67)
[31]
Proportion of inpatient cases Vertebral fracture 0.17 (0.11–0.24), forearm fracture 0.44 (0.19–0.51) [37,64]
Discount rate 3% (0–7) [28]
Compliance 0.38 (0.30–0.46) [34]
Validity of
diagnosis
X-ray of vertebral fracture P(T+/D+) = 0.66 (0.64–0.68r), P(T-/D-) = 0.95 (0.93–0.97) [54]
Decision rule P(T+/D+) = 0.96 (0.94–0.98), P(T-/D-) = 0.18 (0.16–0.20) [10]
Gradient of risk 60–70 years, hip: 1.95 (1.63–2.33), vertebral/forearm: 1.48 (1.39–1.58) [4]
70–80 years, hip: 1.84 (1.65–2.05), vertebral/forearm: 1.55 (1.48–1.62)
Fracture risk increase in women above
the risk threshold compared with
general population
60–70 years, hip: 4.15 (3.72–4.67), vertebral/forearm: 3.54 (3.43–3.66) Calculated
from [4,14]70–80 years, hip: 1.94 (1.78–2.11), vertebral/forearm: 1.70 (1.64–1.76)
Proportion of clinical vertebral
fractures
0.35 (0.29–0.41) [53]
Proportion of x-rays in women
with back pain
60–70 years 0.35 (0.30–0.40) [52]
*The incidence of hip fractures was not varied because the whole German population was sampled.
†Quality-adjusted-life years were discounted at 3%.
CI, conﬁdence interval, CRF, clinical risk factor; DXA, dual x-ray absorptiometry; RG, gradient of risk, P, probability,T, test, D, disease.
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fore, health policy should aim to increase the availability of
DXA. Only in cases where DXA is not available, the usage of
CRFs alone is justiﬁed. In women aged 60 to 70 years, where
CRFs are superior, there is substantial uncertainty in the results.
Because cost-effectiveness acceptability curves (CEACs) do not
indicate the costs of making a wrong decision, funders should be
careful in adopting CRFs alone instead of DXA plus CRFs.
In this analysis, ICERs were calculated based on an inter-
vention threshold of 30%. Lowering this threshold would
decrease speciﬁcity, and, as a result, treatment costs for false
positives would largely increase. Thus, we would expect a lower
threshold to be less cost-effective. In contrast, raising the thresh-
old above 30% may improve the ICER in women aged 70
years because the number of false positives would decrease.
Table 4 Results of the base-case analysis (costs are presented in €, year 2006)*
Intervention Costs† QALYs Control
Incremental
costs
Incremental
QALYs
ICER
(costs/QALY)
Women aged 60–70 years
No screening 114,040 20.208
CRFs alone 114,318 20.268 No screening 278 0.060 4,607
DXA plus CRFs 118,431 20.471 i) No screening 4,391 0.263 16,696
ii) CRFs alone 4,113 0.203 20,235
Women aged 70–80 years
No screening 103,144 13.276
CRFs alone 107,683 13.490 No screening 4,539 0.214 21,181
DXA plus CRFs 105,037 13.562 i) No screening 1,893 0.286 6,611
ii) CRFs alone Dominates
Women aged 80–90 years
No screening 74,137 7.452
Immediate treatment 76,512 7.686 No treatment 2,375 0.234 10,171
DXA plus CRFs 74,967 7.806 i) No screening 830 0.354 2,346
ii) Immediate treatment Dominates
*Incremental costs and QALYs are presented per high-risk woman treated over lifetime and were discounted at 3%.
†Costs in added years of life are included.
CRF, clinical risk factor; DXA, dual x-ray absorptiometry, ICER, incremental cost-effectiveness ratio, QALY, quality-adjusted life years.
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Figure 3 (a) Cost (€) per quality-adjusted life year gained by combined 10-year risk for hip and vertebral fractures in women aged 60–70 ( =DXA plus CRFs,
H17009 = CRFs alone). (b) Cost (€) per quality-adjusted life year gained by combined 10-year risk for hip and vertebral fractures in women aged 70–80 (DXA plus CRFs).
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Nevertheless, these assumptions could not be tested because of
a lack of data.
Our analysis has several strengths. It considers long-term
follow-up costs of hip fractures in Germany including costs of
hip implants, revision surgery, transportation services, rehabili-
tation care, and long-term care [45]. Moreover, in contrast to
many economic analyses in the ﬁeld of osteoporosis prevention,
which did not consider the costs of case ﬁnding [69], our analysis
includes all screening costs including costs of women being diag-
nosed incorrectly (false-positives). Furthermore, in contrast to
the model by Zethraeus and colleagues [30], our model is able to
consider the occurrence of vertebral and forearm fracture after
hip fracture. The no-memory assumption of Markov models was
avoided by creating health states that correspond to combined
health states [70].
An important limitation is that the number of women at
increased risk in the age group of 60 to 70 years is based solely
on prior vertebral fractures. Additional risk factors to increase
the number of women at high risk could not be used because
their distribution in the German population has not been sufﬁ-
ciently evaluated yet [7]. This results in a lower ICER than that
of screening in women aged 70 and 80 years although fracture
risk increases with age and the ICERs of screening strategies
usually decrease with age. The reason is that the cost-
effectiveness ratio is very sensitive to speciﬁcity that is, based on
this strategy, 95% for screening in women aged <70 years, but
only 20% in women aged 70 years, and 0% in women aged 80
years. If it were possible to calculate the risk increase by com-
bining several risk factors, the detection of more women at risk
would be inevitably attenuated by a signiﬁcant decrease of speci-
ﬁcity in the identiﬁcation of nonosteoporotic women, as shown
in the evaluation of many decision rules for CRFs in osteoporosis
screening [10,12].
There are a number of reasons why the results of our study
are rather conservative. First, when calculating the costs of frac-
ture treatment, analgesics were not considered. A recent cost
analysis showed that osteoporotic patients receive three times
more prescriptions for analgesics than nonosteoporotic patients
do [71] and that those who have received nonsteroidal antiphlo-
gistics were signiﬁcantly more often hospitalized for peptic ulcer
disease than those who have not received nonsteroidal antiphlo-
gistics. Including these and other drug costs in the calculation of
treatment costs for vertebral and forearm fractures would
improve cost-effectiveness of CRFs with and without DXA.
Second, our analysis incorporated an increased risk of subse-
quent fractures for women who have suffered a prior fracture.
This risk increase was determined only by the last fracture
because there were no data available on the relationship between
risk increase and the number of prior fractures. Consideration of
Table 5 Results of the budget impact analysis (in million €)
Age group
(years)
CRFs/no
screening
DXA + CRFs/
no screening
DXA + CRFs/
CRFs alone
60–70 1 46 45
70–80 220 57 -163
80–90 339 72 -267
Total 560 175 -385
CRF, clinical risk factor; DXA, dual X-ray absorptiometry.
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Figure 4 (a) Cost-effectiveness acceptability curves for screening and treatment in women aged 60–70 (b) Cost-effectiveness acceptability curves for screening
and treatment in women aged 70–80 (c) Cost-effectiveness acceptability curves for screening and treatment in women aged 80–90 ( CRFs, --- DXA plus CRFs,
— no screening). CRF, clinical risk factors; DXA, dual x-ray absorptiometry.
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two or more prior fractures would probably further increase the
risk of a subsequent fracture and improve the cost-effectiveness
ratio of CRFs with and without DXA. If these data become
available, individual patient-level models could be more accurate
in simulating the relationship between the number of prior frac-
tures and subsequent fractures than between cohort-based
approaches [72]. Moreover, by considering only the last fracture,
in women with a prior hip or vertebral fracture who have a
forearm fracture, the risk of subsequent fractures decreases. Con-
tinuing the higher risk increase of the prior fracture would
improve the ICERs of CRFs and DXA plus CRFs.
Finally, the fracture states in this model are the same as in the
reference model [30] except for fractures at “other” sites that
were not modeled here. By considering only hip, vertebral, and
forearm fractures, our analysis may have underestimated poten-
tial cost savings from the prevention of fractures at other skeletal
sites. Although studies on alendronate did not show a signiﬁcant
reduction of other fractures [31], a study on risedronate, which
also belongs to the class of bisphosphonates, reported a signiﬁ-
cant reduction of nonvertebral fractures by 39% (deﬁned as
fractures of the clavicle, humerus, wrist, pelvis, hip, or leg) [73].
On the other hand, there are also several reasons why a
screen-and-treat strategy based on CRFs alone may be less cost-
effective than that calculated by the base-case analysis. First,
there is contradictory evidence whether individuals selected for
treatment based on CRFs alone beneﬁt from treatment or not. To
date, efﬁcacy data have to be taken from a population selected by
the WHO criterion of BMD including individuals with osteope-
nia [21]. It remains unclear whether these data reﬂect the true
efﬁcacy of a population with a 30% long-term risk based on
CRFs. In some efﬁcacy trials, however, pharmacological interven-
tions with bisphosphonates have been shown effective in patients
not selected on the basis of low BMD [74–77].
Third, alendronate was assumed to be efﬁcacious in all age
groups although there have not been studies in women above the
age of 80 [31].
Finally, for the state “long-term risk of 30%,” disutility of
women aged 70 to 80 was underestimated. The reason is that an
unknown number of women in this group suffer from prior
fractures causing disutility. If a lower QoL was assumed, the
incremental gain in QoL using CRFs with and without DXA
compared with no intervention would be reduced, and, therefore,
both strategies would become less cost-effective. Nevertheless,
the increase of the ICER would be negligible, as shown in the
sensitivity analysis.
The structure of this Markov cohort model is similar to that
of an established reference model [30] although there are also
some discrepancies: in our model, a state for other osteoporotic
fractures was not modeled, and a woman may suffer a vertebral
or forearm fracture after a hip fracture. As recommended there,
a lifelong time horizon with a cycle length of 1 year was adopted,
effectiveness was assumed to decrease linearly for a given “offset
time,” and increased mortality after hip or vertebral fracture was
modeled. In addition, for all fracture states, a postfracture state
was included to reﬂect the sustained risk increase for subsequent
fractures.
To compare the results of this analysis to those of other
models, we used two cost-effectiveness studies for treatment with
bisphosphonates in postmenopausal women [19,20], which are
also based on long-term fracture risk. In these analyses, interven-
tion thresholds for cost-effectiveness of bisphosphonates in
women at different T-scores with or without prior fracture were
calculated. Although the 5-year baseline risks of hip fracture
were similar (e.g., 7.1% and 12.3% for women with a fracture
history aged 70 and 80 years, respectively, compared with 6.7%
and 12.1%, respectively, in our analysis) [19], the results of these
analyses are quite different from our results. But again, there are
important methodological differences compared with our study:
costs of hip fracture are much lower given that costs beyond the
ﬁrst year after fracture were not included, treatment costs of
false-positives were not considered, the discount rates used for
costs (6%) and beneﬁts (1.5%) differed from our study, and
compliance was not considered in the base case. In addition, the
selection of women at increased risk was based on several other
risk factors such as BMI, history of peripheral fractures, use of
oral glucocorticoids, and history of rheumatoid arthritis [19,20].
Consideration of several risk factors is likely to have decreased
the speciﬁcity of the identiﬁcation of nonosteoporotic women
and thus increased the cost-effectiveness ratio.
If we assumed a societal perspective for our analysis, we
would expect similar results. Copayments for drugs may be
partly outweighed by savings for copayments for fracture treat-
ment. Costs through loss of productivity are of minor importance
because the proportion of women aged >60 years being
employed in Germany is below 15% [78].
We do not know whether our ﬁndings are transferable to
other countries. The main reason is that, for costs and epidemio-
logical data, German sources were preferred as inputs to the
model, so differences in resource consumption and prices may
exist.
There are several important areas for future research. First,
predicting fracture risk based on CRFs is still not accurate
enough. Whereas risk factors such as a prior vertebral fracture
and low BMD can be used for precise measurements of the risk
increase [7], other risk factors such as low BMI and immobility
only are known to be indicators of low BMD [7]. Thus, their
interrelationship has yet to be formalized with more precision.
Second, effectiveness of alendronate has to be shown in clini-
cal trials with patients selected on the basis of CRFs instead of
low BMD [31].
Finally, this analysis compared different screen-and-treat
strategies, based on an arbitrary risk threshold of 30% for hip or
vertebral fractures. It would be of general interest to determine
ICERs for different intervention thresholds of screen-and-treat
strategies, using different ratios of hip to vertebral fracture risk or
hip to nonhip–fracture risk. In our analysis, the ICERs of a
combined risk of exact 30% were calculated for a speciﬁc ratio of
hip to vertebral fracture risk. Nevertheless, different risk factors
have different impacts on fracture sites and, thus, different
impacts on QoL, costs, and mortality [20]. For example, if the
absolute fracture risk threshold is reached by risk factors that are
assumed to have a larger impact on the risk of hip fractures than
on vertebral fractures (e.g., use of corticosteroids), treatment is
more cost-effective because hip fractures have a higher impact on
costs and mortality than fractures at other sites do [20].
In summary, CRFs are of considerable value for decision-
making regarding the treatment of postmenopausal osteoporosis.
Nevertheless, until the interrelationships between CRFs have
been evaluated more extensively and until treatment with bis-
phosphonates in women selected by risk factors has shown to be
as effective as in women selected by BMD, their usage should be
combined with DXA. As recommended also by National Insti-
tute for Health and Clinical Excellence, providing treatment
without DXA should be limited to older women only if the
responsible clinician considers it to be clinically appropriate or
unfeasible [20]. As long as DXA is available, the implementation
of any approach based on CRFs alone will result in an uncon-
trolled increase in health expenditures.
Source of ﬁnancial support: None
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